Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013677
Chunk: 15

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 15
---
 not constitute statutory
financial statements for that period or year. The statutory financial statements for December 31, 2024 have been delivered to the UK Registrar
of Companies. The auditor’s report on those accounts was unqualified and did not contain a statement under section 498(2) or 498(3)
of the Companies Act 2006. The auditor’s report did draw attention to a material uncertainty related to going concern and the requirement,
as of the date of the report, for additional funding to be raised by the Company by the fourth quarter of 2025.

Biodexa Pharmaceutical’s
annual reports may be downloaded from the Company’s website at https://biodexapharma.com/investors/financial-reports-and-presentations/#financial-reports
or a copy may be obtained from 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ.

Going Concern – material uncertainty

Biodexa has experienced
net losses and significant cash outflows from cash used in operating activities over the past years as it develops its portfolio. For
the six months to June 30, 2025, the Group incurred a consolidated loss from operations of £3.81million (1H24: loss £3.31
million) and negative cash flows from operating activities of £3.30 million (1H24 £4.81 million). As of June 30, 2025, the
Group had accumulated deficit of £154.13 million.

The Group’s
future viability is dependent on its ability to raise cash from financing activities to finance its development plans until commercialisation,
generate cash from operating activities and to successfully obtain regulatory approval to allow marketing of its development products.
The Group’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue
its business strategies.

The Directors believe
there are adequate options and time available to secure additional financing for the Group and after considering the uncertainties, the
Directors consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements. The Group's
consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business.

As at June 30,
2025, the Group had cash and cash equivalents of £4.04 million. The Directors have prepared cash flow forecasts and considered the
cash flow requirement for the Group for the next three years including